GenFleet Therapeutics (Shanghai) Inc. (HKG:2595)

Market Cap	13.52B
Revenue (ttm)	144.96M +24.4%
Net Income	-2.00B
EPS	-6.75
Shares Out	370.37M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,678,418
Average Volume	4,044,145
Open	37.86
Previous Close	36.98
Day's Range	35.04 - 37.86
52-Week Range	19.60 - 50.20
Beta	n/a
RSI	64.31
Earnings Date	Mar 24, 2026

About HKG:2595

GenFleet Therapeutics (Shanghai) Inc. operates as a biopharmaceutical company that focuses on developing novel treatment options in the fields of oncology that cover different lines of treatments of multiple solid tumors, as well as autoimmune and inflammatory diseases. The company’s products include GFH925, help for the treatment of advanced non-small cell lung cancer, and GFH375, an orally bioavailable small molecule inhibitor of Kirsten rat sarcoma (KRAS) G12C. The company was incorporated in 2017 and is based in Shanghai, China.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2017
• Employees: 94
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2595

Financial Performance

In 2025, HKG:2595's revenue was 130.27 million, an increase of 24.42% compared to the previous year's 104.70 million. Losses were -1.79 billion, 164.8% more than in 2024.

Financial numbers in CNY